The DOI matches its Crossref record.
The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Abstract
Prolonged hyperglycemia, dyslipidemia and oxidative stress in diabetes result in the production and accumulation of AGEs. It is now clear that AGEs contribute to the development and progression of cardiovascular disease in diabetes, as well as other complications. AGEs are thought to act through receptor-independent and dependent mechanisms to promote vascular damage, fibrosis and inflammation associated with accelerated atherogenesis. As a result, novel therapeutic agents to reduce the accumulation of AGEs in diabetes have gained interest as potential cardioprotective approaches. A variety of agents have been developed which are examined in detail in this review. These include aminoguanidine, ALT-946, pyridoxamine, benfotiamine, OPB-9195, alagebrium chloride, N-phenacylthiazolium bromide and LR-90. In addition, it has been demonstrated that a number of established therapies have the ability to reduce the accumulation of AGEs in diabetes including ACE inhibitors, angiotensin receptor antagonists, metformin, peroxisome proliferators receptor agonists, metal chelators and some antioxidants. The fact that many of these inhibitors of AGEs are effective in experimental models, despite their disparate mechanisms of action, supports the keystone role of AGEs in diabetic vascular damage. Nonetheless, the clinical utility of AGE inhibition remains to be firmly established. Optimal metabolic and blood pressure control, that is achieved early and sustained indefinitely, remains the best recourse for inhibition of AGEs until more specific interventions become a clinical reality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Protein carbonylation, cellular dysfunction, and disease progression
Dalle-Donne, I., Aldini, G., Carini, M., Colombo, R., Rossi, R., & Milzani, A. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00407.x · Cited by 831
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
“sion (24), oxidative stress, insulin resistance (7), inflammation (8), dyslipidemia (25), elevated plasma homocysteine (26), the accumulation of advanced glycation end products (27), anemia (28), left ventricular hypertrophy (29), arterial calcification (30), and endothelial dysfunction (31).”
BackgroundSelf-citationAdvanced glycation endproducts and their receptor RAGE in Alzheimer's disease
Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., & Münch, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.016 · Cited by 524
Mason, B. N., Starchenko, A., Williams, R. M., Bonassar, L. J., & Reinhart-King, C. A. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.08.007 · Cited by 363
AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions
Sanajou, D., Ghorbani Haghjo, A., Argani, H., & Aslani, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.001 · Cited by 313
Intervention strategies to inhibit protein carbonylation by lipoxidation‐derived reactive carbonyls
Aldini, G., Dalle‐Donne, I., Facino, R. M., Milzani, A., & Carini, M. (2007) · Medicinal Research Reviews · doi:10.1002/med.20073 · Cited by 289
Quercetin Inhibits Advanced Glycation End Product Formation by Trapping Methylglyoxal and Glyoxal
Li, X., Zheng, T., Sang, S., & Lv, L. (2014) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf504132x · Cited by 288
Molecular Basis of Arterial Stiffening: Role of Glycation – A Mini-Review
Sell, D. R., & Monnier, V. M. (2012) · Gerontology · doi:10.1159/000334668 · Cited by 282
Oxidative Stress in Diabetes and Alzheimer's Disease
Reddy, V. P., Zhu, X., Perry, G., & Smith, M. A. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1013 · Cited by 280
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases
Reddy, V. P., & Beyaz, A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.016 · Cited by 266
Mehta, R., Shangari, N., & O'Brien, P. J. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200600190 · Cited by 42
Dorecka, M., Siemianowicz, K., Francuz, T., Garczorz, W., Chyra, A., Klych, A., & Romaniuk, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71069-7 · Cited by 36
“This process contributes to various vascular pathologies such as an amplification of vascular response, atherosclerosis, diabetic complications and neointimal formation in a response to arterial injury [3, 34, 40, 42, 45].”
Background
Metadata
- Authors
- Thomas, M., Baynes, J., Thorpe, S., & Cooper, M.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-06-01
- Volume
- 6
- Issue
- 4
- Pages
- 453-474
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2052539295
- Cited by
- 159
- References
- 0
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.